The Phase I study of anti-CD22 CAR T cells is a pioneering effort targeting CD22-expressing B cell malignancies in pediatric and young adult populations. Given the high expression of CD22 in B-precursor acute lymphoblastic leukemia (ALL), this therapy addresses a significant unmet need in a patient demographic that has limited treatment options after standard therapies fail. The successful completion of this trial could position the National Cancer Institute (NCI) as a leader in CAR T cell therapy, potentially leading to commercial partnerships or licensing opportunities with biopharmaceutical companies interested in expanding their oncology portfolios. The competitive landscape includes existing CD19-targeted therapies, but the emergence of CD22-targeted therapies may mitigate the risk of antigen escape observed in CD19 therapies. Diligence should focus on the safety profile and long-term efficacy of the treatment, as well as the potential for future trials to expand indications or combinations with other therapies.